drug

Methotrexate

MeSH D008727
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Pakistan Institute of Living and Learning
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Add-on Methotrexate for the Treatment of Schizophrenia
NCT03369795Phase 2Unknown
RCT of Methotrexate Added to Treatment As Usual in Schizophrenia
NCT02074319Phase 1Completed

KOLs & investigators

1
Prof Imran B Chaudhry, MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Pakistan Institute of Living and Learning
company
trial
Add-on Methotrexate for the Treatment of Schizophrenia
PHASE2
trial
RCT of Methotrexate Added to Treatment As Usual in Schizophrenia
PHASE1
trial
indication
Schizophrenia
indication
Schizophreniform Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Prof Imran B Chaudhry, MD
KOL score 5
person